The Optimal Dose Of Drug In Neoadjuvant Chemotherapy Before Surgery For The Patients Suffering From Breast Cancer Stage III

Khaloozadeh, Hamid; Yazdanbakhsh, Pedram; Homaei Shandiz, Fateme

doi:10.22041/ijbme.2008.13551

The Optimal Dose Of Drug In Neoadjuvant Chemotherapy Before Surgery For The Patients Suffering From Breast Cancer Stage III

Document Type : Full Research Paper

Authors

Hamid Khaloozadeh ¹

Pedram Yazdanbakhsh ²

Fateme Homaei Shandiz ³

¹ Associate Professor, Control Engineering School, K.N. Toosi University of Technology

² MSc. Graduate in Control Engineering, Ferdowsi University

³ Associate Professor, Department of' Radiation-Oncology, Medical School, Mashhad University of Medical Sciences

10.22041/ijbme.2008.13551

Abstract

The optimal doses of Doxorubicin and Cyclophosphamide (AC) regimen in pre-operation Neoadjuvant chemotherapy for the patients suffering from stage III breast cancer were investigated. The major benefit of Neoadjuvant chemotherapy is that it can shrink large cancers so that they are small enough to be removed by lumpectomy instead of mastectomy. The optimal regimen designed in this paper was based on the special conditions that every patient had been treated by her/his own physician and the resistance of tumor cells. With respect to these regimen that can achieve non equivalent doses of drug in treatment times for neoadjuvant chemotherapy. The purpose of treating the patients with cancer in neoadjuvant chemotherapy could be either destroying the cancer cells or preserving the normal cell populations in the best way, or different cases between these two situations. In this article, by solving a cost function involved with the dynamics of both cancer cells and normal cells - using the appropriate weighting coefficients suggested by the treating physician- the optimal doses of AC drugs for the patients suffering from breast cancer at stage III were computed by the proposed optimal controller.

Keywords

chemotherapy

Neoadjuvant chemotherapy

Stage III breast cancer

Growth models

Optimal drug programming

Subjects

[1] Way L.W., Surgical Diagnosis & Treatment; 2000; p:276-297.

[2] Carpenter A., Loscalzo G., CECIL Essentials of Medicine, 5th Ed ; 2001

[3] Martin R.B., Optimal control drug scheduling of cancer chemotherapy automation; 1992; 28: 1113- 1123.

[4] Bojkov B., Hansel R., Luus R., Application of direct search optimization to optimal control problems; Hung J. Ind. Chem; 1993; 21:177-185

[5] Luus R., Jaakola H., Optimization by direct search and systematic reduction of the size of search region; AlChE J., 1973; 19:760-766

[6] Luus R., Keil F.J., Optimal drug scheduling of cancer chemotherapy by direct search optimization; Hung J. Ind. Chem., 1995; 23:55-58

[7] Tan K.C., Khor E.F., Cai J., et al, Automating the drug scheduling of cancer chemotherapy via evolutionary computation; Art. Intel, Med, 2002;25:169-185

[8] Floares A., Floares C., Cucu M., Lazar L., Adaptive Neural Networks Control of Drug Dosage Regimens in Cancer Chemotherapy; IEEE 2003;154-159

[9] Devita V.T., Hellman S., Rosenberg S.A., Principles and practice of Oncology; 7th Ed; 2005.

[10] Harirchi I., Karbakhsh M., Kashefi A., Momtahen A.J., Breast Cancer in Iran; Results of a Multi-center study, Asian Pacific journal of cancer prevention, 2004; 5: 24-27.

[11] Hamacher H.W., Optimization methods in cancer radiation therapy; 2003.

[12] Holder A., Radiotherapy treatment design and linear programming; Department of mathematics, Trinty university; 2002.

[13] Khavari B., Biological celology; 1990.

[14] Petrovski A., Mccal J., Computational optimization of cancer chemotherapies using genetic algorithms ; 2000

[15] Schwartz G.F.R, Hortobagyi G.N and the Consensus Conference Committee. Proceedings of the Consensus Conference on Neoadjuvant Chemotherapy in Carcinoma of the Breast, Philadelphia PA. Cancer. 2004; 100:2512-2532

[16] Fisher B., Brown A., Mamounas E., et al; Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer; findings from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of Clinical Oncology; 1997; 15: 2483- 2493.

[17] Bear H.D., Anderson S., Brown A., et al; The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide; Preliminary Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology; 2003;21:4165- 4174

[18] Hardman J.G., Limbird L.E., The Pharmacological basis of therapeutics; 10th Ed; 2000.

[19] Tatro D.S; Drug interaction facts: Herbal Supplements and Food. St. Louis, MO: Facts and Comparisons; 2004.

[20] Coldman A.J., Murray J.M., Optimal control for a stochastic model of cancer therapy ; Elsevier, Mathematical Biosciences; 2000;168:187-2000

[21] Pourbadakhshan K., Khaloozadeh H., Optimal Control for Cancer Chemotherapy using Genetic Algorithm; WSEAS transactions on biology and biomedicine, Issue 1, Volume 2, January 2005.